



File No. BIO/CT/23/000097

Dated 02-12-2024

To,

M/s Roche Products (India) Pvt. Ltd.,  
146-B, 166A, Unit Nos. 7,8,9,  
8<sup>th</sup> floor, R City Office, R City Mall,  
Lal Bahadur Shastri Marg,  
Ghatkopar (West), Mumbai – 400086.

Subject: Application for grant of permission to conduct Phase IV clinical trial entitled “A multi-center, Open-Label, Single Arm Phase IV Study to Assess The Safety And Effectiveness Of Ocrelizumab in Multiple Sclerosis (RMS and PPMS) patients in India (Overture)” vide Protocol No.: ML45008, Version 2.0 dated 24.06.2024 - regarding

Ref. No.: Your Application No. BIO/CT04/FF/2023/38428 dated 19-JUL-2023

Sir,

With reference to your application No.BIO/CT04/FF/2023/38428 dated 19-JUL-2023, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- (I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8.
- (II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:  
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:  
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial.
- (VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

- (VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal.
- (IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination.
- (X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI.
- (XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter.
- (XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter.
- (XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorized by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial.
- (XIV) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority.
- (XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial.
- (XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (XVII) The firm shall submit the Clinical Study Report after completion of the study.

RAJEEV SINGH  
RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI  
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL  
ORGANISATION, ou=CENTRAL DRUGS STANDARD CONTROL  
ORGANISATION, email=rajeev.singh@cdsc.gov.in,  
2.5.4.20=f2d7189b10b910b5a2634475025f1a110860a9  
1f8877348040a3ee361b, postalCode=110002, st=Delhi,  
serialNumber=657f5e47d940985d8f03bd4902d0e1fe73cfa12  
a1a126ea94fa5701124a19013, cn=RAJEEV SINGH  
RAGHUVANSHI  
Date: 2024.12.09 11:03:37 +05'30'

(Dr. Rajeev Singh Raghuvanshi)  
Drugs Controller General (India)  
Licensing Authority

## FORM CT-06

(See rules 22, 25, 26, 29 and 30)

### PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licensing Authority hereby permits M/s Roche Products (India) Pvt. Ltd., 146-B, 166A, Unit Nos. 7,8,9, 8<sup>th</sup> Floor, R City Office, R City Mall, Lal Bahadur Shastri Marg, Ghatkopar (West), Mumbai (India) - 400086 Telephone No.: 022-33941443, 022-33941415, 022-33941413 FAX: 022- 33941054 E-mail: VIPUL.GUPTA@ROCHE.COM to conduct Phase IV clinical trial entitled "A multi-center, Open-Label, Single Arm Phase IV Study to Assess The Safety And Effectiveness Of Ocrelizumab in Multiple Sclerosis (RMS and PPMS) patients in India (Overture)" vide Protocol No.: ML45008, Version 2.0 dated 24.06.2024 in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi  
Date: 02-Dec-2024

**RAJEEV SINGH**  
**RAGHUVANSHI**

Digitally signed by RAJEEV SINGH RAGHUVANSHI  
DN: cn=IN, o=CENTRAL DRUGS STANDARD CONTROL  
ORGANISATION, ou=CENTRAL DRUGS STANDARD CONTROL  
ORGANISATION,  
2.5.4.20=42d7189b1c9981bb5a263a4a73d025ff4b11b680a  
91f08773480400343ee361b, postalCode=110002, st=Delhi,  
serialNumber=6575e47d9409858f03bdc902d0e1fe73cfa1  
2a1a126ea94fa5701124a19013, cn=RAJEEV SINGH  
RAGHUVANSHI  
Date: 2024.12.09 11:03:58 +05'30'

(Dr. Rajeev Singh Raghuvanshi)  
Drugs Controller General (India)  
Central Licensing Authority

सत्यमेव जयते

**Annexure:****Details of new drug or investigational new drug:**

Names of the new drug or investigational new drug:	Ocrelizumab 300mg concentrate for solution for infusion (rDNA origin)		
Dosage form:	300mg/10ml (30mg/ml) in a single-dose vial		
Composition:	Each vial contains:		
	<b>Ingredient</b>	<b>Unit Formula per vial</b>	<b>Pharmacopoeial specification</b>
	Ocrelizumab	300 mg	In-house
	Sodium Acetate Trihydrate	21.4 mg	USP/Ph.Eur./JP
	Glacial Acetic Acid	2.5 mg	USP/Ph.Eur./JP
	$\alpha,\alpha$ -Trehalose Dihydrate	400 mg	NF/Ph.Eur./JP
	Polysorbate 20	2.0 mg	NF/Ph.Eur./JPE
Water for injection	Q.S. 10.0mL	USP/Ph.Eur./JP	
Indication:	Ocrelizumab is indicated for the treatment of: 1. Relapsing forms of Multiple Sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. 2. Primary Progressive MS in adults		

**Details of clinical trial site(s):**

S.No.	Name and Address of Clinical Trial Site(s)	Ethics Committee Details	Name of Principal Investigator
1.	PGIMER, Nehru Hospital, Department of Neurology, Ground Floor, Block A, Sector 12, Chandigarh - 160012	Institutional Ethics Committee, Post Graduate Institute of Medical Education and Research, Room No. 6006, IEC Office, 6th Floor, PN Chuttani Block, Chandigarh - 160012, India EC Reg. No.: ECR/25/Inst/CH/2013/RR-20	Dr Dheeraj Khurana
2.	Lata Mangeshkar Medical Foundation's, Deenanath Mangeshkar Hospital & Research Centre, Off Karve Road, Erandawane, Pune – 411004, Maharashtra, India	Institutional Ethics Committee, Department of Research, 14th Floor, C-Wing, Super Specialty Building, Deenanath Mangeshkar Hospital and Research Centre, Off Karve Road, Erandawane, Pune – 411004, Maharashtra, India EC Reg. No.: ECR/15/Inst/Maha/2013/RR-22	Dr. Rahul Kulkarni

3.	Artemis Hospital, Sector 51, Gurugram, Haryana-122001, India	Artemis Health Sciences IEC, 2 <sup>nd</sup> Floor, B-wing (ICU), Artemis Hospitals, Sector-51, Gurgaon, Haryana – 122001, India. EC Reg. No.: ECR/53/Inst/HR/2013/RR-19	Dr Manish Mahajan
4.	Max Super Speciality Hospital, 1, press, enclave road, Saket, West Block, New Delhi, 110017, India	Max Healthcare Ethics Committee, Ground Floor, Office of Ethics Committee, West block, Near MS Office, Max Super Speciality Hospital, Saket, (A unit of Max Healthcare Institute Limited) 1, Press enclave Road, Saket, New Delhi, 110017, India. EC Reg. No.: ECR/118/Inst/DL/2013/RR-19	Dr Mukesh Kumar
5.	Sparsh Super Specialty Hospital, Ground Floor, Neurology OPD, #146 Infantry Road, Opp. Police Commissioner's Office, Bangalore-560001, Karnataka, India	Institutional Ethics committee Sparsh Hospital, #146, Infantry Road, Opp. Police Commissioner's Office, Bangalore-560001, Karnataka, India. EC Reg. No.: ECR/520/Inst/KA/2014/RR-20	Dr Rajesh B. Iyer
6.	Sree Chitra Tirunal Institute Of Medical Sciences and Technology, Department Of Neurology, Medical College PO, Thiruvananthapuram-695011, Kerala, India.	IEC SCTIMST, Sree Chitra Tirunal Institute of Medical Sciences and Technology Department of Neurology, Medical College PO, Thiruvananthapuram-695011, Kerala, India. EC Reg. No.: ECR/189/Inst/KL/2013/RR-21	Dr Sruthi Nair